Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Bargaining over Revision Rates Enters Final Stage
December 24, 2007
- JapanBridge to Select Anticancer Drug as Its First Product
December 17, 2007
- METIS Inaugurates 3rd-Phase Plan
December 17, 2007
- New Stock Exchange Market NEO to Stimulate Drug Discovery by Bioventures
December 17, 2007
- Medical Devices to Be Re-priced if They Are 1.7 Times More Expensive than Overseas
December 17, 2007
- BUSINESS NEWS IN BRIEF
December 17, 2007
- MEDICAL DEVICE NEWS IN BRIEF
December 17, 2007
- Re-Pricing Runs Counter to Innovation: Industry
December 17, 2007
- TOPICS／Number of Female MRs Increasing but Their Retention Rates Need Improvement
December 17, 2007
- Council Inaugurated to Promote Development of Vaccines
December 17, 2007
- Pediatric Drugs Adversely Affect Developing Companies
December 17, 2007
- New Rule to Exclude Members Receiving Over \3 Mil. Donations from CDFS Review Process
December 17, 2007
- REGULATORY NEWS IN BRIEF
December 17, 2007
- Eli Lilly Japan to Train Staff for Multinational Clinical Trials
December 17, 2007
- Platelet Formation Promoted by Substance Derived from Peanut Skins
December 17, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
December 17, 2007
- Eisai Ties Up with BioArctic Neuroscience for BAN2401 for Alzheimer's Disease
December 17, 2007
- NBI to Be Fastest-Growing among Top-20 Companies 3 Years in a Row
December 17, 2007
- TSD Japan Licensed COLAL-PRED from Alizyme
December 17, 2007
- Livalo to Rise to 3rd on Statin Market
December 17, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…